Company: KROS
Filing Date: 2025-07-17
Form Type: 8-K
Source: 0001664710-25-000062
Chunk: 0

Company: Keros Therapeutics, Inc.
Filing Date: 2025-07-17
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01 Other Events.

On July 17, 2025, Keros Therapeutics, Inc. (the “ Company”) issued a press release announcing that the first patient was dosed in the Phase 3 RENEW clinical trial of elritercept in adults with transfusion-dependent anemia with very low, low, or intermediate risk myelodysplastic syndromes. The dosing of the first patient triggers a $10.0 million milestone payment to the Company under its global license agreement with Takeda Pharmaceuticals U. S. A., Inc. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and, other than the quotes contained therein, is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.